Results 51 to 60 of about 5,807 (256)

Revolutionizing cancer immunotherapy: T cell engagers beyond hematologic malignancies toward solid tumors

Frontiers in Immunology
T cell engagers (TCEs) are a class of T cell–redirecting therapeutics that enhance antitumor immunity by bringing T cells into close proximity with malignant cells.
Xinyi Wu, Ping Li, Ping Li, Tao Li, Qiwen Fan, Hao Wu, Hao Wu   +6 more
doaj   +1 more source

Consensus Standards and Recommendations for Developmental and Cognitive Surveillance, Screening, and Evaluation in Sickle Cell Disease: Executive Summary From the National Alliance of Sickle Cell Centers Neurocognitive Workgroup

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Neurodevelopmental and neurocognitive difficulties are prevalent among individuals with sickle cell disease and warrant prompt identification and support. This Special Report provides an executive summary of standards and recommendations for surveillance, screening, and evaluation for development and cognition across the lifespan developed by ...
Alyssa M. Schlenz, Donna Murdaugh, Andrew M. Heitzer, Jennifer N. Longoria, Wendy Santos‐Modesitt, Arianna Martin, Judy Cavazos, Jeff Schatz, Catherine R. Hoyt, Alison King, Eboni I. Lance, Steven Hardy, Marsha Treadwell   +12 more
wiley   +1 more source

Natural Killer Cells in Paediatric Soft Tissue Sarcomas: A Systematic Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Paediatric soft tissue sarcomas (pSTS) are a rare and heterogeneous group of malignant tumours arising in tissues of mesenchymal origin. The role of natural killer (NK) cells in pSTS remains poorly understood, with evidence fragmented across small preclinical studies and early‐phase clinical trials.
Raya Dean, Lara V. Graham, Christina Putnam, Rosa Gomes Alves Martins, Daniel T. Harding, Tim J. Underwood, Zoë S. Walters, Matthew D. Blunt   +7 more
wiley   +1 more source

Determining Parental Factors for Clinical Trial Attrition in Pediatric Acute Lymphoblastic Leukemia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background/Objectives Despite high enrollment rates on Children's Oncology Group (COG) protocols, attrition after initial consent is challenging, introducing bias and prolonging trial completion. While adult oncology literature has identified predictors of withdrawal, little is known about caregiver decision‐making for child participation in ...
Kimberly L. Stathas, Jakob Q. Weiss, Kellee N. Parker, Cathy Lee‐Miller   +3 more
wiley   +1 more source

Administering Blinatumomab via Continuous Intravenous Infusion in Pediatric Patients—A Single‐Institution Retrospective Review

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Blinatumomab, a CD19xCD3 bispecific T‐cell engager, has become standard therapy for children with de novo B‐cell acute lymphoblastic leukemia (B‐ALL). This retrospective review describes the experience of blinatumomab administration in pediatric patients.
Julia M. Hurley, Ryleigh Krueger, Kellie Joyce, James Stanley, Mary Waskerwitz‐Freyer, Marielle Klunder, David J. Hoogstra   +6 more
wiley   +1 more source

Recent advances on blinatumomab for acute lymphoblastic leukemia

Experimental Hematology & Oncology, 2019
Although complete remission rate of B cell acute lymphoblastic leukemia (B-ALL) has improved significantly over the past few decades, patients with relapsed/refractory ALL still have dismal outcome.
Juanjuan Zhao, Yongping Song, Delong Liu
doaj   +1 more source

Occurrence of Extramedullary Relapses in Pediatric Acute Lymphoblastic Leukemia After Treatment With Blinatumomab

Pediatric Blood &Cancer, EarlyView.
ABSTRACT We report a retrospective single‐center analysis of pediatric patients with relapsed or refractory B‐cell precursor acute lymphoblastic leukemia focusing on relapses outside of the typical locations, bone marrow, central nervous system, or testes.
Johanna Kunz, Martin Ebinger, Michaela Döring, Markus Mezger, Ursula Holzer, Rupert Handgretinger, Peter Lang, Manon Queudeville   +7 more
wiley   +1 more source

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma

Journal for ImmunoTherapy of Cancer, 2020
Background Targeted and effective treatment options are needed for solid tumors, including glioblastoma (GBM), where survival rates with standard treatments are typically less than 2 years from diagnosis.
Shannon A Kreuser, Harrison Chinn, Kole R DeGolier, Lisa R Matsumoto, Richard G Ellenbogen, Courtney A Crane, Jennifer L Gardell, Brooke Prieskorn, Stephanie Balcaitis, Amira Davis   +9 more
doaj   +1 more source

Change in Mental Health and Resilience in Childhood Cancer Survivors After Attending a Person‐Centred State‐of‐the‐Art Late Effects Clinic—on Behalf of the PanCareFollowUp Consortium

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Person‐centred follow‐up care based on evidence‐based clinical practice guidelines and providing individualised information should help to inform and reassure survivors about their medical and psychosocial situation and provide treatment and support where needed.
Gisela Michel, Mieke Rijken, Marietta Kokla, Charlotte Sleurs, Jurgen Lemiere, Line Elmerdahl Frederiksen, Luzius Mader, Cecilia Follin, Sara Oberti, Jeanette Falck Winther, Selina R. van den Oever, Leontien C. M. Kremer, Helena J. H. van der Pal, Peter Spreeuwenberg, Eline Bouwman, Jeroen te Dorsthorst, Samira Essiaf, Elizabeth A. M. (Lieke) Feijen, Hannah Gsell, Riccardo Haupt, Maria van Helvoirt, Rosella P. M. G. Hermens, Lars Hjorth, Tomas Kepak, Katerina Kepakova, Anita Kienesberger, Monica Muraca, Marleen Renard, Carina Schneider, Roderick Skinner, Anne Uyttebroeck, Deveny Vanrusselt, Sabine Verschueren, Jacqueline Loonen, Saskia M. F. Pluijm, Katharina Roser, the PanCareFollowUp consortium   +36 more
wiley   +1 more source

CAR T cells and T cell engagers for autoimmunity—lessons from hematology

Bone Marrow Transplantation
Abstract Autoimmune diseases are driven by dysregulated immune responses against self-antigens, resulting in chronic inflammation and progressive tissue damage. Chimeric antigen receptor (CAR) T cell therapy and T cell engagers, initially developed for the treatment of hematologic malignancies, have demonstrated that they can mediate ...
Sarah Kayser, Arnon Nagler
openaire   +2 more sources